Multiple sclerosis MS affects about 2. Most people are diagnosed between the ages of 20 and 50, though it can occur in young children and significantly older adults. MS presents in different forms, but generally it is a progressive disease, worsening over time.
There is exciting and innovative research and progress occurring related to the potential of many types of stem cells for slowing MS disease activity and for repairing damage to the nervous system. In light of the urgent need for more effective treatments for MS, particularly for those with more progressive forms of the disease, we believe that the potential of all types of cell therapies must be explored. Stem cell therapy is any treatment that uses or targets stem cells, which are the types of cells that differentiate into many different specialized cells in our bodies.
Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis MS using human embryonic stem cells, offering a promising new therapy for more than 2. The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow. The study was led by ImStem Biotechnology Inc.
People with multiple sclerosis sometimes become desperate and will travel to other countries for experimental stem cell treatments. Faced with an incurable condition, people with multiple sclerosis will sometimes seek risky alternative treatments as their disabilities increase. And it comes with a high price.
Arch Neurol. Hematopoietic stem cell transplantation HSCT was proposed as a treatment for multiple sclerosis MS in based on favorable results in animal models including experimental autoimmune encephalomyelitis. In general, these trials suffered from higher than anticipated toxic reactions including treatment-related and disease-related mortality, continued loss of brain volume as seen on magnetic resonance imaging MRIand, at least in some patients, continued progressive disability despite marked attenuation or absence of gadolinium-enhancing lesions on MRI.
Multiple Sclerosis MS is caused by an immune mediated attack targeting components of the myelin sheath. At present there are no FDA-approved treatments that specifically target the abnormal immune responses in MS. Current approaches, such as interferon, copaxone, or immune suppressants all act in a nonspecific manner blocking immune responses against the myelin sheath.
Multiple sclerosis MSa complex disorder of the central nervous system CNSis characterized with axonal loss underlying long-term progressive disability. Currently available therapies for its management are able to slow down the progression but fail to treat it completely. Moreover, these therapies are associated with major CNS and cardiovascular adverse events, and prolonged use of these treatments may cause life-threatening diseases.
This uses your own stem cells, which are collected and then injected back into your body. Early results have been encouraging and understanding how best to treat people with stem cells is improving. AHSCT has not been formally assessed for use in the NHS outside clinical trials, but a small number of centres have begun to provide it on the NHS under specific circumstances to a very small number of people.
Multiple sclerosis MS is a common neurological disease and a major cause of disability, particularly affecting young adults. It is characterized by patches of damage occurring throughout the brain and spinal cord, with loss of myelin sheaths - the insulating material around nerve fibres that allows normal conduction of nerve impulses - accompanied by loss of cells that make myelin oligodendrocytes. In addition, we now know that there is damage to nerve cells neurones and their fibres axons too, and that this occurs both within these discrete patches and in tissue between them.